One of the promising applications of DNA array technology is in the design of anti-angiogenic tumor therapies through the identification of potential target genes in endothelial cells. This task requires reproducible procedures for the preparation of multiple highquality RNA samples from various in vitro and in vivo sources of endothelial cells. Unfortunately, endothelial cells possess high levels of RNase activity, which leads to the instability of RNA preparations (4) . In our laboratory, we use several types of membrane-based radiolabeled DNA arrays for hybridization with cDNA prepared from different cell lines and tissue samples (Atlas ® Human cDNA Expression Array; BD Biosciences Clontech, Palo Alto, CA, USA), "Known Genes" GeneFilters ® GF211 (Research Genetics, Huntsville, AL, USA), and human cytokine array (R&D Systems, Minneapolis, MN, USA). Several RNA isolation techniques were used to prepare RNA samples, including TRI ZOL ® Atlas Pure RNA kit, mRNA Separator kit (all from BD Biosciences Clontech), and MessageMaker ™ (Invitrogen, Carlsbad, CA, USA) with subsequent treatment of samples with DNase I (Worthington Biochemical, Lakewood, NJ, USA). We found that these techniques led to degraded RNA or did not produce quantities of RNA from endothelial cells (<0.1 µ g/10 6 cells for mRNA Separator and MessageMaker) sufficient for our experiments. We require at least 15-20 µ g RNA per experimental point for spectrophotometric quantitation, electrophoresis, and preparation of cDNA. Primary cultures of human endothelial cells have limited potential for growth, exhibit alterations in the expression of various proteins after the first 2-3 passages (2, 3) , and are expensive [a culture of 0.5 ×10 6 human umbilical vein endothelial cells (HUVEC; Clonetics, Walkersville, MD, USA) costs $189]. Therefore, when using endothelial cells, it is important to use an RNA isolation technique that will produce sufficient quantities of highly intact RNA free from DNA contamination for use in DNA array experiments.
In our experiments with different transformed and normal human cell lines and human xenografts in athymic nude mice, we found that the use of the TRI ZOLreagent led to preparations of total RNA with a sufficient yield (the average of 12.9 µ g/10 6 cells). These RNA samples had high levels of integrity (based on agarose gel electrophoresis), purity (based on A 260 /A 280 ratios), and the ability to hybridize with all types of arrays tested. Figure 1A shows an example of a low background and high level of specific signals (5) for an Atlas Human cDNA Expression Array hybridized with TRI ZOL -purified RNA from U87 glioblastoma cells (hybridization of the membrane in Figure 1A used the RNA shown in Figure 2A , lane 5). However, when we applied the TRI ZOL technique of RNA purification to human endothelial cell lines, we found that it often produced partially or completely degraded RNA preparations ( Figure 2A,  lanes 1-4) . Out of 59 samples tested in eight independent experiments, 38 (64%) were partially or completely degraded. When RNA samples were intact or moderately degraded immediately following TRI ZOL purification, they were easily degraded during the subsequent DNase I treatment ( Figure 2B , lanes 2 and 3). Similar data were obtained for RNA samples isolated directly from the endothelium of umbilical cords. It is possible that this RNA instability is the result of high levels of RNases or nonspecific nucleases expressed by endothelial cells. Indeed, several reports have demonstrated the instability of RNA isolated from endothelial cells and a high level of endothelial RNase activity from both endogenous and exogenous sources. One example of an exogenous RNase is angiogenin, which is taken up by proliferating endothelial cells and has been shown to exhibit strong RNase activity (6) . To prevent RNA degradation during the isolation procedure, several types of RNase inhibitors were used [RNase Out ™ (Invitrogen), SUPERase In ™, and RNAsecure ™ (both from Ambion, Austin, TX, USA)], but these did not lead to reproducible results during the RNA purification from endothelial cells.
In our previous experiments examining gene expression by RNA Northern analysis, we used a column-based purification of total RNA (RNeasy ® kit; Qiagen, Valencia, CA, USA) (1). The simplicity and reproducibility of this technique led us to apply it to the purification of RNA from human endothelial cells for use in our DNA array experiments. RNA samples obtained using the RNeasy kit were intact ( Figure 2B , lane 4) and yielded [ 32 P]-labeled cDNA with a high specific activity (10 7 cpm/ µ g cDNA). However, the hybridization of cDNA from these samples resulted in a high, nonspecific background on the arrays ( Figure 1B) . The treatment of the RNA samples with DNase I for 2 h at 4°C did not lead to the complete removal of this background. Therefore, we combined this approach with a TRI -ZOL -based purification method because TRI ZOL and subsequent phenol/chloroform extraction further purified the RNA by removing the traces of genomic DNA and protein. This combination resulted in the purification of RNA samples from endothelial cell lines, HU -VEC and human microvascular endothelial cells (HMEC), with high integrity, purity, and low background after hybridization with DNA arrays (Figure 1C and Figure 2B , lanes 5 and 6). It was important to determine whether the differences in background hybridization were connected with the RNA preparation technique or were simply the result of differences in the cell lines used, the functional status of the cells, or the hybridization conditions. To do this, we hybridized RNA samples prepared using three different techniques (TRI ZOL + DNase I; RNeasy + DNase I; and RNeasy + TRI ZOL + DNase I) from the same sample of cells (HUVEC) (Figure  1, D-F) . For the evaluation of background, we used blank membranes provided by BD Biosciences Clontech. Figure 1 , D and E, shows that the TRI -ZOL and RNeasy techniques resulted in low and high backgrounds, respectively. However, their combination resulted in RNA pure enough to remain undegraded after the DNase I treatment ( Figure  2B , lanes 5 and 6) and in low background on the membranes ( Figure 1F ). Compared with the high frequency of RNA degradation that was observed when the TRI ZOLmethod was used (64%), our technique reduced the ratio of degraded samples to 7.5%. The average yield was 11.8 µ g/10 6 cells, which is compatible with TRI ZOLalone (described earlier).
The major steps of our technique are as follows: ( 
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